

### ASSIGNMENT

WHEREAS, Shanghai SynTheAll Pharmaceuticals, ASSIGNOR, corporation of China, with a mailing address in care of Shanghai SynTheAll Pharmaceuticals, 5<sup>th</sup> Floor, Building 5, 90 Delin Road, Pudong New District, Shanghai, P.R. China 200131, in relation to the inventions for:

### CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION

for which applications for patents have been filed:

- ☒ on August 20, 2022, TW Application No. 111130121 (Docket No.122787.00181);
- ☒ on August 20, 2022, U.S. Non-Provisional Application No. 17/885,213 (Docket No.122787.00182); and
- ☒ on August 20, 2022, International Application No. PCT/US2022/039994I (Docket No.122787.00183).

WHEREAS, Biomea Fusion, Inc. a corporation organized and existing under the laws of the United States of America, and having an office for the transaction of business at 900 Middlefield Road, 4<sup>th</sup> Floor, Redwood City, CA 94063, herein referred to as "ASSIGNEE," is desirous of obtaining my entire right, title and interest in, to and under the said invention and the said application.

NOW, THEREFORE, in consideration of good and valuable consideration, the recipient, herein referred to as "ASSIGNEE," is desirous of obtaining my entire right, title and interest in, to and under the said invention and the said application.

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR has sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, unto the said ASSIGNEE, its successors, legal representatives and assigns, my entire right, title and interest in, to and under the said invention, and the said application and all applications claiming priority thereto and all divisions, renewals and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said application under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof;

AND ASSIGNOR HEREBY authorizes and requests the Commissioner for Patents and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument;

AND ASSIGNOR HEREBY covenants and agrees that ASSIGNOR has full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed, and will not execute, any agreement in conflict herewith;

AND ASSIGNOR HEREBY further covenants and agrees that ASSIGNOR will communicate to the said ASSIGNEE, its successors, legal representatives and assigns, any facts known to ASSIGNOR respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid the said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper protection for said invention in all countries.

Date 19-Sep-2022

Liying Chen  
[ADD Name and Title]

Shanghai SynTheAll Pharmaceuticals

VP. PDS

Date \_\_\_\_\_

[Ravi UPASANI]

Senior Vice President Intellectual Property  
Biomea Fusion, Inc.

Date 19-Sep-2022

Cheng Ting Cheng Ting  
Witness (sign and print name)